The Medical Letter on Drugs and Therapeutics
Ponatinib (Iclusig) for CML and Ph+ ALL
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Ponatinib (Iclusig – Ariad), a tyrosine kinase inhibitor, has been approved by the FDA for treatment of chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant to prior tyrosine kinase inhibitor therapy. It is the fifth tyrosine kinase inhibitor approved for the treatment of CML or Ph+ ALL.1-4

STANDARD TREATMENT — Imatinib, the first tyrosine kinase inhibitor approved for treatment of CML, is the standard first-line treatment for all phases of CML. Primary treatment of chronic-phase CML with imatinib has achieved 5-year complete cytogenetic response and overall survival rates of 87% and 89%, respectively. For the 20-30% of patients with primary or secondary resistance to imatinib,5 dasatinib or nilotinib are often used and have ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ponatinib (Iclusig) for CML and Ph+ ALL
Article code: 1424b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian